VERIFY试验:Rusfertide对比安慰剂在放血依赖的真性红细胞增多症患者中的III期研究
VERIFY Part 1a是一项双盲III期试验,纳入293例放血依赖且血细胞比容控制不佳的真性红细胞增多症患者,随机接受Rusfertide或安慰剂联合或不联合细胞减灭治疗。Rusfertide组临床应答率77%显著高于安慰剂组33%,并显著减少放血次数、维持血细胞比容<45%及改善患者报告症状。
要点
- Rusfertide显著提高临床应答率(77% vs 33%,P<.0001)。
- Rusfertide减少平均放血次数(0.5 vs 1.8,P<.0001)并维持血细胞比容<45%。
- Rusfertide改善疲劳和骨髓纤维化症状评分(P=.0252和.0240)。
核心结论
- 在放血依赖且接受标准治疗的真性红细胞增多症患者中,Rusfertide显著改善血细胞比容控制、减少放血需求并改善患者报告症状。
研究设计与样本
- VERIFY Part 1a为32周、双盲、随机对照III期试验,按1:1随机分配至Rusfertide或安慰剂,联合或不联合细胞减灭治疗。
- 共纳入293例患者,Rusfertide组147例,安慰剂组146例。
主要发现
- Rusfertide组113例(77%)达到临床应答,安慰剂组48例(33%),P<.0001。
- Rusfertide组平均放血次数为0.5±1.2次,安慰剂组为1.8±1.5次,P<.0001。
- Rusfertide组92例(63%)维持血细胞比容<45%,安慰剂组21例(14%),P<.0001。
- PROMIS疲劳SF-8a T评分和MFSAF TSS7改善优于安慰剂,P分别为.0252和.0240。
- 最常见不良事件为注射部位反应、贫血和疲劳,未报告死亡。
关键数值与推荐
- 主要疗效终点为临床应答(第20-32周无放血资格)。
- 关键次要终点包括基线至第32周平均放血次数、维持血细胞比容<45%的比例及患者报告结局变化。
临床怎么用
- Rusfertide可作为放血依赖且血细胞比容控制不佳的真性红细胞增多症患者的治疗选择,减少放血需求并改善症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide is a subcutaneous, injectable, hepcidin mimetic peptide that suppresses erythrocytosis. The phase III VERIFY trial evaluated the efficacy and safety of rusfertide in phlebotomy-dependent patients with PV and poorly controlled hematocrit. METHODS: In VERIFY Part 1a (32 weeks), patients requiring frequent phlebotomy were randomly assigned (1:1, double-blind) to receive rusfertide or placebo with or without cytoreductive therapy. The primary efficacy end point was clinical response (absence of phlebotomy eligibility; weeks 20-32). Key secondary end points (baseline to week 32) included mean number of phlebotomies, proportion of patients who maintained hematocrit <45%, and mean change from baseline in patient-reported outcomes (Patient-Reported Outcomes Measurement Information System [PROMIS] Fatigue Short Form 8a [SF-8a] T score and Myelofibrosis Symptom Assessment Form [MFSAF] Total Symptom Score-7 items [TSS7]). RESULTS: Patients (N = 293) were randomly assigned to rusfertide (n = 147) or placebo (n = 146). Significantly more patients (n = 113, 77%) achieved a clinical response with rusfertide versus placebo (n = 48; 33%; P < .0001). Compared with placebo, rusfertide reduced mean ± standard deviation number of phlebotomies (0.5 ± 1.2 v 1.8 ± 1.5; P < .0001) and was superior in maintaining hematocrit <45% (n = 92 [63%] v n = 21 [14%]; P < .0001). Rusfertide led to a significant improvement in the PROMIS Fatigue SF-8a T-score and MFSAF TSS7 versus placebo (P = .0252 and .0240, respectively). Injection site reactions, anemia, and fatigue were the most common adverse events. No deaths were reported. CONCLUSION: Rusfertide significantly improved hematocrit control, reduced the need for phlebotomy, and improved patient-reported symptoms versus placebo in phlebotomy-dependent patients with PV who were also receiving standard-of-care therapy.
引用
- Kuykendall AT, Bankar A, Pettit KM, et al. VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy. J Clin Oncol. 2026. PMID: 42868322. doi:10.1200/JCO-26-00992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。